Vanda Pharmaceuticals Inc. (VNDA)

Nasdaq: VNDA · Pharmaceutical Preparations · Washington, DC · filing with the SEC since 2005

Full chart Alerts Compare

Grade6.0

◀ Past 7.4● Present 6.0▶ Future 4.5

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$216M+8.7%

Net income-$220M-1066.5%

Earnings per share$-3.74-1033.3%

Operating cash flow-$109M-594.6%

Cash$84.9M-17.1%

Debtn/a

Shareholders’ equity$327M-39.2%

Shares, diluted58.9M+1.3%

Return on equity-67.4%

The recordfrom its filings

Filings in 202664

Newest filingNov 10 · SCHEDULE 13G

Annual reportFeb 12, 2026

Quarterly reportOct 29, 2026

Next report due10-K by Mar 16

Insider sales, 12 months$2.8M

Insider buys, 12 months$0.00

Patents granted109

Filer categoryAccelerated filer

Trailing twelve months to Sep 2026Revenue $229MNet income -$275MCash from operations -$139Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Oct 29, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Oct 28, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Oct 27, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Oct 9, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Aug 19, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Aug 13, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Aug 6, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Aug 5, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Vanda Pharmaceuticals Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Washington, DC. Fanapt was 54% of fiscal 2025 revenue.

Newest on the record

Large holder notice on Nov 10. Before it, insider trade report on Nov 5.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 16, 2027.

About VNDA

Vanda Pharmaceuticals Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Washington, DC. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $216 million and a loss of $220 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersWashington, DC

Business modelProduct business

ExchangeNasdaq

Filing since2005

Fiscal year endsDec 31

SEC number (CIK)1347178

Peers on fileTBPH, RYTM, PHAR, ARDX

Who runs it

Financial performance

In fiscal 2025 Vanda Pharmaceuticals’s revenue was $216.1 million, up 8.7% from $198.8 million the year before. It made a net loss of $220.5 million.

Annual report, filed Feb 12, 2026.

Financial statements

The grade

Vanda Pharmaceuticals grades 6.0 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Eight of the nine metrics are read as filed and one is an SI estimate, each with its reasoning.

◀ Past7.4

● Present6.0

▶ Future4.5

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton VNDA · research, not advice